Condition: Solid Tumors · ER+ Breast Cancer · Triple Negative Breast Cancer, TNBC · Sponsor: Jacobio Pharmaceuticals Co., Ltd.
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
This description comes directly from the study's public registry record.
Jacobio Pharmaceuticals · (781) 918-6670 · clinicaltrials@jacobiopharma.com
Always discuss trial participation with your own doctor first.
| Henry Ford Health System | Detroit, Michigan, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Recruiting |
| University of Utah Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Jilin Cancer Hospital | Changchun, Jilin, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05490472